Do all angiotensin II type 1 receptor blockers have the same beneficial effects?

British Journal of Pharmacology

Volumn 151, Issue 7, 2007, Pages 912-913

  Miura, S ^a   Saku, K ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Affinity; Binding complex; Class effects; Dissociation; Insurmountability

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 TYPE 1 RECEPTOR BLOCKER; CANDESARTAN; ENALAPRIL; G PROTEIN COUPLED RECEPTOR; LOSARTAN; OLMESARTAN; TELMISARTAN; UNCLASSIFIED DRUG; VALSARTAN;

BINDING AFFINITY; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; HEART FAILURE; HUMAN; HYPERTENSION; HYPERTROPHY; PRIORITY JOURNAL; PROTEINURIA; REVIEW;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; HUMANS; IMIDAZOLES; MOLECULAR STRUCTURE; PROTEIN BINDING; RECEPTOR, ANGIOTENSIN, TYPE 1; TETRAZOLES;

EID: 34547567853     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707324     Document Type: Review

References (12)

1. Arakawa K (2004). Significance of suppressing angiotensin by ARB. Prog Med 24: 1757-1762.
2. Awad AS, Webb RL, Carey RM, Siragy HM (2004). Renal nitric oxide production is decreased in diabetic rats and improved by AT1 receptor blockade. J Hypertens 22: 1571-1577.
3. Berellini G, Cruciani G, Mannhold R (2005). Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists. J Med Chem 48: 4389-4399.
4. Iwata A, Miura S, Imaizumi S, Kiya Y, Nishikawa H, Zhang B et al. (2007). Do valsartan and losartan have the same effects in the treatment of coronary artery disease? Circ J 71: 32-38.
5. Koh KK, Han SH, Chung WJ, Ahn JY, Jin DK, Kim HS et al. (2004). Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. Am J Cardiol 93: 1432-1435.
6. Le MT, Liefde IV, Pugsley MK, Vauquelin G (2007). Molecular characterization of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor. Br J Pharmacol 151: 952-962 (this issue).
7. Matsuda H, Hayashi K, Homma K, Yoshioka K, Kanda T, Takamatsu I et al. (2003). Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertens Res 26: 875-880.
8. Miura S, Saku K, Karnik SS (2003). Molecular analysis of the structure and function of the angiotensin II type 1 receptor. Hypertens Res 26: 937-943.
9. Miura S, Fujino M, Saku K (2005). Angiotensin II receptor blocker as an inverse agonist: a current perspective. Curr Hypertens Rev 1: 115-121.
10. Miura S, Fujino M, Hanzawa H, Kiya Y, Imaizumi S, Matsuo Y et al. (2006). Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem 281: 19288-19295.
11. Smith DH, Dubiel R, Jones M (2005). Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 5: 41-50.
12. Yasuda Y, Akazawa H, Komuro I (2005). Significance of ARB from the viewpoint of cardioprotection for cardiac hypertrophy. Prog Med 25: 2521-2526.